Combined ultrasound-biochemical screening of fetal trisomia in the first trimester and double biochemical screening in the second trimester at nonrisk pregnancies;Kombinirani ultrazvučno-biokemijski probir fetalnih trisomija u prvom i dvostruki biokemijski probir u drugom tromjesečju u neugroženim trudnoćama

Gynaecologia et Perinatologia

Volumn 18, Issue 3, 2009, Pages 123-131

  Tišlarić Medenjak, Dubravka ^a   Zec, Ivana ^a   Košec, Vesna ^b   Ivičević Bakulić, Tomislav ^b   Kuna, Krunoslav ^b   Herman, Radoslav ^b   Butorac, Dražan ^b   Bolanča, Ivan ^b   Ujević, Martina ^c   Radončić, Erden ^c   Boras Slivar, Sanja ^c   Šemnički, Nataša ^c   Tonković Durišević, Ivana ^d   Kralik Oguić, Saša ^e   Lovrić, Boris ^f  

^a KB Sestre Milosrdnice   (Croatia)

^b SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^c Poliklinika Vili ^*  (Croatia)

^d KBC Zagreb   (Croatia)

^e Endokrinolo ki Laboratory   (Croatia)

^f Ginekolo ki Odjel   (Slovenia)

Author keywords

Alpha fetoprotein; Combined screening; Double biochemical screening; Down's syndrome; Free hCG; Nuchal translucency; PAPP A; Prenatal screening

Indexed keywords

ALPHA FETOPROTEIN; BIOCHEMICAL MARKER; CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; AMNIOCENTESIS; ANEUPLOIDY; ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; CROATIA; CROWN RUMP LENGTH; DOWN SYNDROME; FALSE POSITIVE RESULT; FEMALE; FETUS ECHOGRAPHY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; NUCHAL TRANSLUCENCY MEASUREMENT; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRENATAL SCREENING; RISK FACTOR; SECOND TRIMESTER PREGNANCY; STATISTICAL SIGNIFICANCE; TRISOMY;

EID: 70350235059     PISSN: 13300091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Wald NJ, Watt HC, Hackshaw AK. Integrated screening for Down's syndrome based on tests performed during the first and second trimesters. New Engl J Med 1999;341:461-467
2. 2. Herman A, Dreazen E, Tovbin J, Weinraub Z et al. Comparison between disclosure and non-disclosure approaches for trisomy 21 screening tests. Hum Reprod 2002;17:1358-1362 (Pubitemid 34537376)
3. 3. Wright D, Bradbury D, Benn P et al. Contingent screening for Down syndrome is an efficient alternative to non-disclosure sequential screening. Prenat Diagn 2004;24:762-766 (Pubitemid 39468654)
4. 4. Piatt LD, Greene N, Johnson A et al. Sequential pathways of testing after first-trimester screening for trisomy 21. Obstet Gynecol 2004;104:661-666 (Pubitemid 40458789)
5. 5. Christiansen M, Larsen SO. An increase in cost-effectiveness of first-trimester maternal screening programmes for fetal chromosome anomalies is obtained by contingent testing. Prenat Diagn 2002;22:482-486 (Pubitemid 34716938)
6. 6. Ball RH, Caughey AB, Malone FD et al. First- and secondtrimester evaluation of risk for Down syndrome. Obstet Gynecol 2007;110:10-17. (Pubitemid 47015694)
7. 7. Brajenović-Milić B, Tišlarić D, Bačić J et al. Screening for Down's syndrome and neural tube defect in Croatia: A regional prospective stady. Fetal Diagn Ther 1998;13:367-371 (Pubitemid 29069022)
8. 8. Huderer-Durić K, Škrablin S, Kuvačić I et al. The triple marker test in predicting fetal aneuploidy: A compromise between sensitivity and specificity. Eur J Obstet Gynaecol Reprod Biol 2000;88:49-55. (Pubitemid 30009370)
9. Tišlarić-Medenjak D. Probir dvostrukim biokemijskim testom. Gynaecol Perinatol 2003;12(suppl. 1):67-71.
10. Tišlarić-Medenjak D, Košec V, Kos M et al. Kombinirani ultrazvučno-biokemijski probir fetalnih aneuploidija od 10-14. tjedna trudnoće: prvi rezultati primjene testa u Hrvatskoj. Gynaecol Perinatol 2008;17:195-200.
11. 11. Nicolaides KH, Spencer K, Avigdou K, Faiola S, Falcon O. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies; results of estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol 2005;25:221-226 (Pubitemid 40432687)
12. Barclay L, Lie D. New guidelines recommend universal prenatal screening for Down syndrome. Obstet Gynecol 2007; 109:217-228
13. 13. Cicero S, Bindra R, Rembouskos G et al. Integrated ultrasound and biochemical screening for trisomy 21 using fetal translucency, absent fetal nasal bone, free ß-hCG and PAPP-A at 11 to 14 weeks. Prenat Diagn 2003;23:306-310 (Pubitemid 36457264)
14. 14. Borrel A, Gonce A, Martinez JM et al. First trimester screening for Down syndrome with Ductus venosus Doppler studies in addition to nuchal translucency and serum markers. Prenat Diagn 2005;25:901-905 (Pubitemid 41494985)
15. Huggon IC, De Figuereido DB, Allan LD. Tricuspid regurgitation in the diagnosis of chromosomal anomalies in the fetus at 11-14 weeks of gestation. Heart 2003;89:1071-1073
16. Borenstein M, Persico N, Strobl I, Sonek J, Nicolaides KH. Frontomaxillary and mandibulomaxillary facial angles at 11+0 to 13+6 weeks in fetuses with trisomy 18. Ultrasound Obstet Gynecol 2007;3:928-933
17. Nicolaides KH, Snijders RJ, Cukle RS. Correct estimation of parameters for ultrasound nuchal translucency screening. Prenat Diagn 1998;18:519-523
18. 18. Maymon R, Bergman M, Segal S et al. Sequential first and second trimester screening tests: correlation of the markers' levels in normal versus Down syndrome affected pregnancies. Prenat Diagn 2001;21:1175-1179 (Pubitemid 34118204)
19. 19. Malone FD, Canick JA, Ball RH et al. First-trimester or second-trimester screening, or both, for Down's syndrome. New Engl J Med 2005;353:2001-2011 (Pubitemid 41609093)
20. 20. Wright D, Bradbury I, Cuckle H et al. Three-stage contingent screening for Down syndrome. Prenat Diagn 2006;26: 528-534 (Pubitemid 43989187)
21. Benn PA, Campbell WA, Zelop CM et al. Stepwise sequential screening for fetal aneuplody. Am J Obstet Gynecol 2007;197:312.el-5.
22. 22. Macintosh MC, Wald NJ, Chard T et al. The selective miscarriage of Down's syndrome from 10 weeks of pregnancy. Br J Obstet Gynaecol 1996; 103:1172-1173 (Pubitemid 26371073)
23. 23. Scott F, Peters H, Bonifacio M et al. Prospectice evaluation of a first trimester screening program for Down syndrome and other chromosomal abnormalities using maternal age, nuchal translucency and biochemistry in an Australian population. Australian New Zealand J Obstet Gynecol 2004;44:205-209 (Pubitemid 38979177)
24. 24. Wøjdemann KR, Shalmi AC, Christiansen M et al. Improved first-trimester Down syndrome screening performance by lowering the false-positive rate: a prospective study of 9941 low-risk women. Ultrasound Obstet Gynecol 2005;25:227-233 (Pubitemid 40432688)
25. Soergel P, Pruggmayer M, Schwerdtfeger R et al. Screening for trisomy 21 with maternal age, fetal nuchal translucency and maternal serum biochemistry at 11-14 weeks: A regional experience from Germany. Fetal Diagn Ther 2006;21:264-268
26. 26. De Graaf IM, Cuckle SH, Pajkrt E et al. Co-variables in first trimester serum screening. Prenat Diagn 2000;20:186-189 (Pubitemid 30168823)
27. 27. Liao AW, Heath V, Kametas N, Spencer K, Nicolaides KH. First trimester screening for trisomy 21 in singleton pregnancies achieved by assisted reproduction. Hum Reprod 2001; 7:1501-1504 (Pubitemid 32640332)
28. 28. Tul N, Novak-Antolič Ž. Serum PAPP-A levels at 10-14 weeks of gestation are altered in women after assisted conception. Prenat Diagn 2006;26:1206-1211 (Pubitemid 46032333)
29. 29. Spencer K, Ong CYT, Liao AWJ, Papademetriou D, Nicolaides KH. The influence of fetal sex in screening for trisomy 21 by fetal nuchal translucency, maternal serum free ß-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 2000; 20:673-675 (Pubitemid 30598916)
30. 30. Spencer K, Ong CYT, Liao AWJ, Nicolaides KH. The influence of parity and gravidity on first trimester markers of chromosomal abnormality. Prenat Diagn 2000;20:792-794 (Pubitemid 30807824)
31. 31. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 2003;10: 56-104. (Pubitemid 36734906)
32. 32. Wald NJ, Jonathan PB, Morris JK. Cross-trimester marker ratios in prenatal screening for Down syndrome. Prenat Diagn 2006;26:514-523 (Pubitemid 43989185)
33. Brajenović-Milić B, Tišlarić D, Žuvić-Butorac M et al. Elevated second trimester free beta-hCG as an isolated finding and pregnancy outcomes. Fetal Diagn Ther 2004;19:483-487
34. 34. Duřić K, Škrablin S, Lešin J et al. Second trimester total human chorionic gonadotropin and unconjugated estriol in predicting pregnancy complications other than fetal aneuploidy. Eur J Obstet Gynaecol Reprod Biol 2003;110:12-15 (Pubitemid 37025690)
35. Cuckle H, Arbuzova S, Spencer K et al. Frequency and clinical consequences of extremely high maternal serum PAPP-A levels. Prenat Diagn 2003;23:385-388 (Pubitemid 36596967)
36. De Biasio P, Canini S, Crovo A et al. Early vaginal bleeding and first trimester markers for Down syndrome. Prenat Diagn 2003;23:470-473 (Pubitemid 36775584)
37. Tul N, Pušenjak, S Osredkar J et al. Predicting complications of pregnancy with first trimester maternal serum free-ß-hCG, PAPP-A and inhibin-A. Prenat Diagn 2003;23:990-996 (Pubitemid 38004790)
38. Spencer K, Cowans NJ, Avigdou K et al. First-trimester biochemical markers of aneuploidy and the prediction of smallfor-gestational age fetuses. Ultrasound Obstet Gynecol 2008;31: 15-19 (Pubitemid 351211925)
39. Nicolaides KH, Chervenak FA, McCullough LB et al. Evidence-based obstetric ethics and informed decision-making by pregnant women about invasive diagnosis after first-trimester assessment of risk for trisomy 21. Am J Obstet Gynecol 2005; 193:322-326
40. 40. Weisz B, Pandya P, Chitty L et al. Practical issues drawn from implementation of the integrated test for Down syndrome screening into routine clinical practice. Br J Obstet Gynaecol 2007;114:493-497 (Pubitemid 46393287)
41. Gekas J, Gagnè G, Bujold E et al. Comparison of different strategies in prenatal screening for Down's syndrome: cost effectiveness analysis of computer simulation. Br Med J 2009;338: b138doi10.1136/bmjb138